Retatrutide - Informational Research Article: Scientific & Clinical Overview
Description
Scientific information notice. This page is an independent, educational review of publicly available scientific and clinical literature concerning retatrutide. It is not a product listing, does not offer retatrutide for sale, and does not provide individualized medical, prescribing, or dosing advice. Retatrutide is an investigational substance: as of 2026 no medicinal product containing it holds a marketing authorization in any jurisdiction. Clinical outcomes described here relate to the specific investigational formulations and study populations used in the cited research and cannot be generalized to other materials containing the same active substance.
Quick facts
| Compound class | Triple GIP / GLP-1 / glucagon receptor agonist |
| Development code | LY3437943 |
| Type | Synthetic 39-amino-acid peptide with a C20 fatty-diacid moiety (albumin-binding) |
| Administration in trials | Once-weekly subcutaneous injection |
| Highest level of evidence | Phase 3 randomized controlled trials (first peer-reviewed Phase 3 publication 2026; obesity Phase 3 reported as sponsor topline results) |
| Regulatory status | Investigational. No marketing authorization from the EMA, FDA or any other regulator as of August 2026; media reporting anticipates a regulatory submission no earlier than 2027. |
What is retatrutide?
Retatrutide is a synthetic single-chain peptide of 39 amino acids, developed under the code LY3437943, engineered to activate three metabolic receptors at once: the receptor for glucose-dependent insulinotropic polypeptide (GIP), the receptor for glucagon-like peptide-1 (GLP-1), and the glucagon receptor. Because it engages all three pathways, it is described as a triple agonist, or a GIP/GLP-1/glucagon receptor “tri-agonist”. The molecule is based on the native GIP sequence, modified so that a single peptide can bind and signal through the three receptors.
A defining feature is a C20 fatty-diacid chain attached through a linker. This moiety binds reversibly to serum albumin, which slows clearance and gives retatrutide a long circulating half-life of roughly six days — long enough to support once-weekly subcutaneous administration in the trials that studied it. As with related acylated peptides, elimination is expected to proceed primarily through proteolytic catabolism of the peptide backbone.
The incretins GIP and GLP-1 are gut-derived hormones that amplify insulin secretion after eating; glucagon, by contrast, is a counter-regulatory hormone whose receptor signaling in the liver and other tissues is associated with increased energy expenditure and hepatic lipid handling. By adding glucagon receptor agonism to dual incretin agonism, retatrutide was designed to test whether recruiting an energy-output pathway on top of the appetite- and insulin-related incretin pathways produces greater metabolic effects. The clinical program built around that question — Phase 2 trials in obesity and type 2 diabetes and the Phase 3 TRIUMPH and TRANSCEND programs — is summarized below.
Mechanism of Action
GIP receptor signaling
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin secreted by enteroendocrine K-cells of the upper small intestine in response to nutrient intake. Acting on the GIP receptor, it potentiates glucose-stimulated insulin secretion from pancreatic beta-cells. GIP receptors are also expressed in adipose tissue and regions of the central nervous system.
GLP-1 receptor signaling
Glucagon-like peptide-1 (GLP-1) is an incretin secreted by intestinal L-cells. Through the GLP-1 receptor it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and acts on central pathways associated with satiety. GLP-1 receptor agonism is the established mechanism of an entire drug class used in type 2 diabetes and weight management.
Glucagon receptor signaling
Glucagon is secreted by pancreatic alpha-cells and acts mainly on the liver, where it stimulates glucose output, and on pathways associated with lipid oxidation and energy expenditure. On its own, glucagon receptor agonism raises blood glucose — which is why a glucagon component is only viable when balanced by incretin activity that preserves glycemic control. In the retatrutide program, the glucagon component is the mechanistic candidate for the marked reductions in liver fat and the additional energy-expenditure effect studied in the trials.
Triple agonism
Retatrutide activates the three receptors with a single molecule. The rationale, tested across the Phase 2 program and the Phase 3 TRIUMPH and TRANSCEND programs, is that adding glucagon receptor engagement to GIP/GLP-1 co-agonism may yield greater reductions in body weight and liver fat than incretin agonism alone. Its pharmacology is deliberately biased among the three receptors, and the relative contribution of each pathway to the observed effects remains under investigation.
Pharmacokinetic profile
The following values are drawn from the clinical-pharmacology literature on the investigational compound. No regulatory product information exists for retatrutide, so an authoritative label-level source is not yet available.
- Half-life: approximately 6 days, supporting the once-weekly dosing studied in the trials.
- Protein binding: extensive reversible binding to serum albumin via the C20 fatty-diacid moiety.
- Metabolism and elimination: expected to proceed via proteolytic cleavage of the peptide backbone, as with related acylated peptides.
Exact pharmacokinetic parameters have been reported only in the scientific literature; there is no regulatory product information to consult.
Research Data
Regulatory status
Retatrutide is an investigational active substance in late-stage clinical development. As of August 2026 no medicinal product containing retatrutide holds a marketing authorization anywhere in the world — not from the European Medicines Agency, not from the U.S. Food and Drug Administration, and not from any other regulator. Following the completion of the core Phase 3 obesity trials, media and industry reporting anticipates that the sponsor (Eli Lilly) will file for regulatory approval, with a submission not expected before 2027; until such an application is reviewed and granted, retatrutide remains an unapproved investigational compound in every jurisdiction.
Important regulatory distinction. Because no authorized retatrutide medicine exists, any material offered under the name “retatrutide” has no approved pharmaceutical counterpart at all: no authority has evaluated any retatrutide product for quality, safety, or efficacy. Clinical-trial results obtained with the sponsor’s investigational formulation do not establish the identity, quality, safety, or efficacy of any other material said to contain the same substance.
Clinical research
Major published trials and sponsor-reported Phase 3 results are summarized below. Doses named describe how the trials were designed; they are not dosing instructions. Sponsor topline announcements are identified as such: they are company communications, not peer-reviewed publications.
Phase 2, obesity (48 weeks). A randomized, double-blind, placebo-controlled Phase 2 trial in 338 adults with obesity (or overweight with a complication), without diabetes, testing 1, 4, 8 and 12 mg once weekly. At 48 weeks the reported mean body-weight change reached −24.2% in the 12 mg group versus −2.1% with placebo; at 24 weeks the highest dose showed −17.5%. Weight reduction had not plateaued at 48 weeks in the higher-dose groups. Jastreboff AM, et al. N Engl J Med. 2023;389:514–526.
Phase 2, type 2 diabetes (36 weeks). A randomized, double-blind, placebo- and active-controlled Phase 2 trial in 281 adults with type 2 diabetes. HbA1c reductions reached approximately −2.0 percentage points at the higher doses, with body-weight reductions of up to about −16.9% — the largest weight effect reported in a type 2 diabetes trial of an incretin-based agent at that time. Rosenstock J, et al. Lancet. 2023;402:529–544.
Phase 2a substudy, metabolic dysfunction-associated steatotic liver disease (MASLD). A substudy of the Phase 2 obesity trial in 98 participants with MASLD and at least 10% liver fat. At 48 weeks, mean relative liver-fat reductions of more than 80% were reported at the higher doses, with the majority of participants in those groups reaching normal liver-fat content (below 5%). Sanyal AJ, et al. Nat Med. 2024;30:2037–2048.
TRANSCEND-T2D-1 — type 2 diabetes (Phase 3, 40 weeks). The first peer-reviewed Phase 3 publication for retatrutide: a double-blind, randomized trial in adults with type 2 diabetes inadequately controlled with diet and exercise. Reported HbA1c reduction reached approximately −2.0 percentage points, with mean body-weight reduction of up to about −16.8% at 40 weeks. Lancet. 2026 (published 13 June 2026; PMID 42250575).
TRIUMPH-1 — obesity, without diabetes (Phase 3, sponsor topline). In May 2026 the sponsor announced topline results of this randomized, placebo-controlled trial in 2,339 adults with obesity (or overweight with a complication), testing 4, 9 and 12 mg. As communicated, mean body-weight reductions at 80 weeks were approximately −17.6%, −23.7% and −25.0% for the three doses versus about −3.9% with placebo, with figures up to about −28.3% at the highest dose depending on the analysis population and estimand, and reductions described as reaching about 30% at 104 weeks in participants with severe obesity. The announcement also described reductions in triglycerides, non-HDL cholesterol, systolic blood pressure and waist circumference. A peer-reviewed publication of TRIUMPH-1 had not appeared at the time this page was written; the figures above are company-reported.
TRIUMPH-2 and TRIUMPH-3 (Phase 3, sponsor topline). In July 2026 the sponsor reported topline results in obesity with type 2 diabetes (TRIUMPH-2; mean weight reductions up to about −20.8%) and in obesity with established cardiovascular disease (TRIUMPH-3; up to about −22.6% at 80 weeks). As with TRIUMPH-1, these are company communications pending peer-reviewed publication.
Clinical evidence matrix
| Research area | Trial | Phase | Participants | Duration | Comparator | Primary reported finding |
|---|---|---|---|---|---|---|
| Obesity | Phase 2 obesity | 2 | 338 | 48 wk | Placebo | Up to ~−24.2% mean body weight |
| Type 2 diabetes | Phase 2 T2D | 2 | 281 | 36 wk | Placebo + active | HbA1c up to ~−2.0 pp; weight up to ~−16.9% |
| Liver fat (MASLD) | Phase 2a substudy | 2a | 98 | 48 wk | Placebo | >80% mean relative liver-fat reduction (higher doses) |
| Type 2 diabetes | TRANSCEND-T2D-1 | 3 | Multicenter RCT | 40 wk | Placebo | HbA1c ~−2.0 pp; weight up to ~−16.8% |
| Obesity | TRIUMPH-1 | 3 | 2,339 | 80 wk | Placebo | Sponsor topline: up to ~−25–28% mean body weight |
| Obesity + T2D | TRIUMPH-2 | 3 | Sponsor topline | 80 wk | Placebo | Sponsor topline: up to ~−20.8% mean body weight |
| Obesity + CVD | TRIUMPH-3 | 3 | Sponsor topline | 80 wk | Placebo | Sponsor topline: up to ~−22.6% mean body weight |
Figures are as reported in the primary publications or, where marked, in sponsor topline communications, and should be verified against those sources.
Clinical development timeline
- 2020–2022 — Phase 1 clinical pharmacology of LY3437943 in healthy participants and type 2 diabetes.
- 2023 — Phase 2 results published: obesity (N Engl J Med) and type 2 diabetes (Lancet).
- 2024 — MASLD liver-fat substudy published (Nat Med); Phase 3 TRIUMPH and TRANSCEND programs ongoing.
- 2026 — first peer-reviewed Phase 3 publication (TRANSCEND-T2D-1, Lancet, June 2026); sponsor topline results for TRIUMPH-1 (May 2026) and TRIUMPH-2/-3 (July 2026).
- Anticipated — regulatory submission reported as expected no earlier than 2027; no authorization exists as of August 2026.
Limitations and interpretation
- Trials use specific inclusion/exclusion criteria; results do not necessarily generalize to everyone.
- Interventions were investigational pharmaceutical formulations made to defined standards; data do not establish equivalence of other materials.
- Sponsor topline announcements are company communications: endpoints, estimands and subgroup figures may be presented selectively until the peer-reviewed publication appears.
- Trial durations are finite; long-term outcomes beyond the studied periods are not established by these trials alone.
- Secondary and exploratory outcomes carry less certainty than primary endpoints; Phase 2 signals need Phase 3 confirmation.
- Because many secondary metabolic outcomes accompany substantial weight loss, direct drug effects are difficult to isolate.
- The trials were industry-sponsored, which should be disclosed when interpreting the results.
How incretin mechanisms differ
This comparison is mechanistic and informational; it is not advice on which agent to use. Retatrutide is a triple agonist of the GIP, GLP-1 and glucagon receptors and is investigational. Tirzepatide is a dual GIP/GLP-1 receptor agonist and is the active substance of authorized medicines. Semaglutide is a GLP-1 receptor agonist acting on a single incretin pathway and is likewise the active substance of authorized medicines. The three molecules differ in receptor profile, clinical evidence base and regulatory status.
Possible Side Effects
The most frequently reported adverse events in the retatrutide trials were gastrointestinal and generally mild-to-moderate: nausea, diarrhea, vomiting, and constipation, dose-dependent and most common during dose escalation. In the Phase 2 obesity trial these events were the most frequent reason for treatment discontinuation, a pattern consistent with the wider incretin class.
The Phase 2 obesity publication also reported a dose-dependent increase in heart rate, peaking at around 24 weeks of treatment and declining thereafter, and cutaneous sensory symptoms (such as skin hyperaesthesia or dysaesthesia) more often than with placebo. The risk of hypoglycemia is low when incretin-based agents are used without insulin or insulin secretagogues, because the insulinotropic effect is glucose-dependent.
Because retatrutide has no marketing authorization, no regulatory safety profile exists: there is no product information, no labeled warnings section, and no post-marketing safety surveillance. The complete characterization of its safety is an explicit objective of the ongoing Phase 3 program, and the trial publications are the only authoritative safety sources available.
This section summarizes findings reported in clinical trials. It is not a personal risk assessment and is not medical advice.
Product Attributes
| Compound | Retatrutide |
| Development code | LY3437943 |
| CAS number | 2381089-83-2 |
| Class | Triple GIP/GLP-1/glucagon receptor agonist |
| Peptide length | 39 amino acids (single chain) |
| Structural feature | C20 fatty-diacid moiety via a linker (albumin-binding) |
| Molecular formula | C221H342N46O68 |
| Approximate molecular weight | ~4,731.4 Da |
| Reported plasma half-life | ~6 days |
| Route studied | Subcutaneous, once weekly |
| Regulatory status | Investigational; no marketing authorization in any jurisdiction |
Numerical values are drawn from published chemical and clinical-pharmacology sources and should be verified against them.
Scientific References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. DOI 10.1056/NEJMoa2301972 (PMID 37366315).
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529–544. DOI 10.1016/S0140-6736(23)01053-X (PMID 37385280).
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048. DOI 10.1038/s41591-024-03018-2 (PMID 38858523).
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026 (published 13 June 2026; PMID 42250575).
- Eli Lilly and Company. Topline results announcement for the Phase 3 TRIUMPH-1 trial of retatrutide in obesity, May 2026. investor.lilly.com (company communication, not a peer-reviewed publication).
- Eli Lilly and Company. Topline results announcements for the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, July 2026. investor.lilly.com (company communications).
- ClinicalTrials.gov. TRIUMPH-1 (NCT05929066); TRIUMPH-2 (NCT05929079) — trial registrations and protocols. clinicaltrials.gov
This page is provided solely as an educational review of publicly available scientific literature. It does not constitute a product offer, medical advice, prescribing information, or a recommendation to use any substance. Retatrutide is an investigational compound: no medicinal product containing it has been authorized by any regulator, and clinical-trial results obtained with the sponsor’s investigational formulation do not establish the identity, quality, safety, or efficacy of any other material said to contain the same substance. For the status of any future authorization, consult the relevant medicines authority.
Didn't find the answer to your question?
View all frequently asked questionsRegister and log in to see our full catalog.
Part of our catalog is visible only to registered account holders.
Registration is free and asks for nothing but an email address.
Members only
Entries reserved for account holders
What an account opens up
Members-only products
Part of our range is listed only inside a customer account.
Discounts and promotions
Access to our running offers, promo codes and account pricing.
Guides and protocols
Reconstitution, storage and pen handling, written for our own products.
Community and priority support
Your order history in one place and a direct line to our team.
